FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018009626> ?p ?o ?g. }

• W2018009626 endingPage "733" @default.
• W2018009626 startingPage "726" @default.
• W2018009626 abstract "To investigate the tolerance and efficacy of a modified concurrent chemoradiation (CCRT) protocol for patients with invasive bladder cancer unfit for radical cystectomy.Twenty-three muscle-invasive bladder cancer patients who were unfit for or unwilling to receive radical cystectomy were enrolled in this study. All patients had transitional cell carcinoma of bladder, and distribution of stage was 14 (61%), 1 (4%), and 8 (35%) for T3a, T3b, and T4, respectively. This study included a relatively old-age population, with the median age being 75 and 70% of patients over 70 years old. Patients were treated with maximal transurethral resection of the bladder tumor followed by curative CCRT. The chemotherapy (C/T) regimen was comprised of cisplatin, 50 mg/m(2) intravenously (i.v.) on Day 1; 5-fluorouracil (5-FU), 500 mg/m(2)/day by continuous i.v. infusion on Days 1-3; and leucovorin, 50 mg/day by continuous i.v. infusion on Days 1-3. Chemotherapy course was repeated at 21-day intervals. The radiation dose was 44-45 Gy to whole pelvis and 60-61.2 Gy to bladder, with a daily fraction of 1.8-2 Gy. The completeness of the CCRT protocol was defined as patients receiving at least 55 Gy of radiotherapy to the whole bladder and at least three courses C/T.Seventy-four percent of patients (17/23) completed the CCRT protocol. Radiation Therapy Oncology Group (RTOG) Grade 3 acute toxicities were observed in 4 patients, which included leucopenia, vomiting, genitourinary (GU) tract infection, and diarrhea. No treatment-related deaths occurred during the CCRT period. RTOG Grade 3 or more late complications were observed in 3 patients; one of them died of radiation cystitis superimposed with GU infection. Of the 18 patients whose response to CCRT was evaluated, a complete tumor response was documented in 16 patients (89%). With a median follow-up of 3 years, the 3-year overall survival (OS) and disease-free survival (DFS) for all patients was 69% and 65% respectively. Meanwhile, the 3-year overall and DFS rates for patients who completed CCRT vs. those who did not complete CCRT were 82% vs. 33% and 75% vs. 33%, respectively (p = 0.18 for OS and p = 0.04 for DFS).Concurrent cisplatin, 5-FU, leucovorin, and radiotherapy for treatment of invasive bladder cancer is a feasible and promising treatment even for relatively old patients. Our results are comparable to those in recent studies by using combined modality treatment or neoadjuvant chemotherapy plus radical cystectomy. Consequently, this novel protocol warrants a prospective clinical trial and may be a safe, effective alternative to radical cystectomy." @default.
• W2018009626 created "2016-06-24" @default.
• W2018009626 creator A5001591030 @default.
• W2018009626 creator A5010864255 @default.
• W2018009626 creator A5020279524 @default.
• W2018009626 creator A5039846270 @default.
• W2018009626 creator A5054130749 @default.
• W2018009626 creator A5057019053 @default.
• W2018009626 creator A5065720039 @default.
• W2018009626 creator A5068656065 @default.
• W2018009626 creator A5072983458 @default.
• W2018009626 creator A5091683814 @default.
• W2018009626 date "2003-07-01" @default.
• W2018009626 modified "2023-10-16" @default.
• W2018009626 title "Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer" @default.
• W2018009626 cites W1774531900 @default.
• W2018009626 cites W1786366031 @default.
• W2018009626 cites W1828142674 @default.
• W2018009626 cites W1847455118 @default.
• W2018009626 cites W1926736670 @default.
• W2018009626 cites W1932620090 @default.
• W2018009626 cites W1987702547 @default.
• W2018009626 cites W2013446192 @default.
• W2018009626 cites W2024639509 @default.
• W2018009626 cites W2028522982 @default.
• W2018009626 cites W2043945205 @default.
• W2018009626 cites W2072167013 @default.
• W2018009626 cites W2084623142 @default.
• W2018009626 cites W2094331414 @default.
• W2018009626 cites W2167805334 @default.
• W2018009626 cites W2257225020 @default.
• W2018009626 cites W2336213711 @default.
• W2018009626 cites W2395940194 @default.
• W2018009626 cites W2470654889 @default.
• W2018009626 cites W4293241248 @default.
• W2018009626 cites W4376546343 @default.
• W2018009626 doi "https://doi.org/10.1016/s0360-3016(03)00124-x" @default.
• W2018009626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12788178" @default.
• W2018009626 hasPublicationYear "2003" @default.
• W2018009626 type Work @default.
• W2018009626 sameAs 2018009626 @default.
• W2018009626 citedByCount "43" @default.
• W2018009626 countsByYear W20180096262013 @default.
• W2018009626 countsByYear W20180096262014 @default.
• W2018009626 countsByYear W20180096262015 @default.
• W2018009626 countsByYear W20180096262016 @default.
• W2018009626 countsByYear W20180096262017 @default.
• W2018009626 countsByYear W20180096262018 @default.
• W2018009626 countsByYear W20180096262020 @default.
• W2018009626 countsByYear W20180096262021 @default.
• W2018009626 countsByYear W20180096262023 @default.
• W2018009626 crossrefType "journal-article" @default.
• W2018009626 hasAuthorship W2018009626A5001591030 @default.
• W2018009626 hasAuthorship W2018009626A5010864255 @default.
• W2018009626 hasAuthorship W2018009626A5020279524 @default.
• W2018009626 hasAuthorship W2018009626A5039846270 @default.
• W2018009626 hasAuthorship W2018009626A5054130749 @default.
• W2018009626 hasAuthorship W2018009626A5057019053 @default.
• W2018009626 hasAuthorship W2018009626A5065720039 @default.
• W2018009626 hasAuthorship W2018009626A5068656065 @default.
• W2018009626 hasAuthorship W2018009626A5072983458 @default.
• W2018009626 hasAuthorship W2018009626A5091683814 @default.
• W2018009626 hasConcept C121608353 @default.
• W2018009626 hasConcept C126322002 @default.
• W2018009626 hasConcept C126894567 @default.
• W2018009626 hasConcept C141071460 @default.
• W2018009626 hasConcept C2775910329 @default.
• W2018009626 hasConcept C2776694085 @default.
• W2018009626 hasConcept C2778065480 @default.
• W2018009626 hasConcept C2778239845 @default.
• W2018009626 hasConcept C2779762690 @default.
• W2018009626 hasConcept C2780352672 @default.
• W2018009626 hasConcept C2780456651 @default.
• W2018009626 hasConcept C2781413609 @default.
• W2018009626 hasConcept C2908647359 @default.
• W2018009626 hasConcept C509974204 @default.
• W2018009626 hasConcept C71924100 @default.
• W2018009626 hasConcept C99454951 @default.
• W2018009626 hasConceptScore W2018009626C121608353 @default.
• W2018009626 hasConceptScore W2018009626C126322002 @default.
• W2018009626 hasConceptScore W2018009626C126894567 @default.
• W2018009626 hasConceptScore W2018009626C141071460 @default.
• W2018009626 hasConceptScore W2018009626C2775910329 @default.
• W2018009626 hasConceptScore W2018009626C2776694085 @default.
• W2018009626 hasConceptScore W2018009626C2778065480 @default.
• W2018009626 hasConceptScore W2018009626C2778239845 @default.
• W2018009626 hasConceptScore W2018009626C2779762690 @default.
• W2018009626 hasConceptScore W2018009626C2780352672 @default.
• W2018009626 hasConceptScore W2018009626C2780456651 @default.
• W2018009626 hasConceptScore W2018009626C2781413609 @default.
• W2018009626 hasConceptScore W2018009626C2908647359 @default.
• W2018009626 hasConceptScore W2018009626C509974204 @default.
• W2018009626 hasConceptScore W2018009626C71924100 @default.
• W2018009626 hasConceptScore W2018009626C99454951 @default.
• W2018009626 hasIssue "3" @default.
• W2018009626 hasLocation W20180096261 @default.
• W2018009626 hasLocation W20180096262 @default.
• W2018009626 hasOpenAccess W2018009626 @default.

• next